Phase 1 study to evaluate the safety, pharmacokinetic and hormone-release profile of TAK-448 when administered as single and multiple dose SC bolus or infusions in prostate cancer patients.
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2015
At a glance
- Drugs TAK 448 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- 20 Nov 2015 New trial record